Ami Organics Limited (AMIORG) - Total Liabilities
Based on the latest financial reports, Ami Organics Limited (AMIORG) has total liabilities worth Rs2.29 Billion INR (≈ $24.79 Million USD) as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Ami Organics Limited cash conversion from operations to assess how effectively this company generates cash.
Ami Organics Limited - Total Liabilities Trend (2014–2025)
This chart illustrates how Ami Organics Limited's total liabilities have evolved over time, based on quarterly financial data. Check AMIORG asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Ami Organics Limited Competitors by Total Liabilities
The table below lists competitors of Ami Organics Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen Edadoc Technology Co. Ltd. A
SHE:301366
|
China | CN¥621.62 Million |
|
Luye Pharma Group Ltd
F:LUP
|
Germany | €15.49 Billion |
|
Winall Hi tech Seed
SHE:300087
|
China | CN¥4.22 Billion |
|
Ramsay Generale De Sante
PA:GDS
|
France | €5.41 Billion |
|
Medartis Holding AG
SW:MED
|
Switzerland | CHF204.50 Million |
|
El Puerto de Liverpool S.A.B. de C.V
MX:LIVEPOLC-1
|
Mexico | MX$133.37 Billion |
|
China Railway Tielong Container Logistics Co Ltd
SHG:600125
|
China | CN¥2.16 Billion |
|
CAP S.A
SN:CAP
|
Chile | CL$3.10 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Ami Organics Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Ami Organics Limited market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.91 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ami Organics Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ami Organics Limited (2014–2025)
The table below shows the annual total liabilities of Ami Organics Limited from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs2.29 Billion ≈ $24.79 Million |
-44.53% |
| 2024-03-31 | Rs4.13 Billion ≈ $44.68 Million |
+138.84% |
| 2023-03-31 | Rs1.73 Billion ≈ $18.71 Million |
+26.62% |
| 2022-03-31 | Rs1.37 Billion ≈ $14.77 Million |
-44.54% |
| 2021-03-31 | Rs2.46 Billion ≈ $26.64 Million |
+105.15% |
| 2020-03-31 | Rs1.20 Billion ≈ $12.99 Million |
-8.29% |
| 2019-03-31 | Rs1.31 Billion ≈ $14.16 Million |
+33.76% |
| 2018-03-31 | Rs978.86 Million ≈ $10.59 Million |
+39.68% |
| 2017-03-31 | Rs700.79 Million ≈ $7.58 Million |
+7.87% |
| 2016-03-31 | Rs649.65 Million ≈ $7.03 Million |
+46.40% |
| 2015-03-31 | Rs443.74 Million ≈ $4.80 Million |
+58.84% |
| 2014-03-31 | Rs279.37 Million ≈ $3.02 Million |
-- |
About Ami Organics Limited
Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson's, antidepressant, and anticoagulant applications, as wel… Read more